815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
RH reported fourth quarter and fiscal 2025 results on March 31, 2026, with net revenues up 3.7% to $843 million and net income up 107% to $29 million for the quarter. For fiscal 2025, net revenues rose 8.1% to $3.44 billion and net income rose 72% to $125 million. However, the company guided to first-quarter 2026 revenue growth of negative 2% to negative 4%, so shareholders face a weaker near-term sales outlook even as profits improved.
Q4 2025 diluted EPS was $1.46 versus $0.69 a year earlier; net revenues were $842.6 million versus $812.4 million.
Fiscal 2025 diluted EPS was $6.31 versus $3.62; free cash flow was $252 million for the year.
Q1 2026 outlook: revenue growth of negative 2% to negative 4% and adjusted EBITDA margin of 5.5% to 6.5%.
Fiscal 2026 outlook: revenue growth of 4% to 8% and adjusted EBITDA margin of 14% to 16%.
PVH reported fourth quarter 2025 revenue of $2.505 billion, up 6% on a reported basis, and non-GAAP EPS of $3.82, above its $3.20 to $3.35 guidance. The company also gave a 2026 outlook projecting non-GAAP EPS of $11.80 to $12.10 and at least $300 million in 2026 stock repurchases, but its GAAP results showed a fourth quarter loss of $(3.46) per share.
Q4 2025 revenue was $2.505 billion, up 6% reported and flat in constant currency; non-GAAP EPS was $3.82 versus guidance of $3.20 to $3.35.
Q4 2025 GAAP EPS was $(3.46), compared with $2.83 in the prior year period.
2026 outlook projects non-GAAP EPS of $11.80 to $12.10 versus $11.40 in 2025, with revenue projected to increase slightly.
PVH plans at least $300 million in stock repurchases in 2026, after more than $560 million in 2025.
NIKE reported fiscal 2026 third-quarter results for the period ended February 28, 2026. Revenue was flat at $11.3 billion on a reported basis and down 3 percent on a currency-neutral basis, while net income fell 35 percent to $0.5 billion and diluted earnings per share fell to $0.35 from $0.54. For shareholders, the quarter shows lower profit on flat sales, with gross margin also down.
Revenues were $11.3 billion, flat reported and down 3 percent currency-neutral; NIKE Direct fell 4 percent to $4.5 billion.
Net income was $0.5 billion, down 35 percent; diluted EPS was $0.35 versus $0.54 a year earlier.
Gross margin decreased 130 basis points to 40.2 percent, primarily due to higher tariffs in North America.
The company returned about $609 million to shareholders through dividends in the quarter, up 3 percent.
BriaCell Therapeutics filed interim financial statements for its subsidiary BriaPro Therapeutics for the three and six months ended January 31, 2026, showing larger losses than a year earlier and a shareholders' deficit of $1,618,141. The filing states there is a material uncertainty about BriaPro's ability to continue as a going concern, and that it depends entirely on BriaCell for funding until it raises additional financing.
Six-month net loss was $472,231, compared with $233,185 in the prior-year period; three-month net loss was $227,493, compared with $151,062.
Six-month research and development expenses were $433,307, compared with $130,023 a year earlier.
Amounts due to related parties were $1,606,112 at January 31, 2026, and cash and cash equivalents were $1.
On February 18, 2026, BriaPro agreed to acquire BriaCell's license to Soluble CD80; the transaction closed March 30, 2026, with 23,972,589 shares issued to BriaCell and a credit facility of up to $3,000,000.
nCino reported fourth-quarter and fiscal 2026 results, with total revenues up 6% year over year and a GAAP net income attributable to nCino compared with a loss a year earlier. The company also gave fiscal 2027 guidance of $639.0 million to $643.0 million in total revenues and entered a $100 million accelerated share repurchase funded by a $200 million term loan, which adds debt.
Q4 fiscal 2026 total revenues were $149.7 million, up from $141.4 million; GAAP net income attributable to nCino was $8.3 million, versus a $18.6 million loss a year earlier.
Fiscal 2027 guidance: total revenues of $639.0 million to $643.0 million and free cash flow of $132.0 million to $137.0 million.
A $100 million accelerated share repurchase with Wells Fargo is expected to settle in the second quarter of fiscal 2027, funded by a $200 million senior secured term loan maturing October 28, 2029.
Cash, cash equivalents and restricted cash were $88.7 million at January 31, 2026, and $213.5 million was outstanding under the revolving credit facility.
MiNK Therapeutics reported fourth-quarter and full-year 2025 results on March 31, 2026, along with a filing that furnishes its press release. The company's net loss widened for the full year, and it ended 2025 with $13.4 million in cash, which it says provides a runway through 2026 together with $3.0 million raised since year end under its at-the-market sales program.
Full-year 2025 net loss was $12.5 million, or $2.93 per share, compared with $10.8 million, or $2.86 per share, in 2024.
Fourth-quarter 2025 net loss was $2.6 million, or $0.56 per share, compared with $2.5 million, or $0.62 per share, in the fourth quarter of 2024.
Cash balance was $13.4 million at year end 2025; the company raised an additional $3.0 million through its at-the-market program after year end.
The press release cites a C-Further Consortium collaboration providing up to $1.1 million in non-dilutive funding; the filing reports no revenue figures.
TD SYNNEX reported fiscal first-quarter 2026 results for the period ended February 28, 2026, with revenue of $17.2 billion, up 18.1% year over year, and GAAP diluted EPS of $4.04 versus $1.98 a year earlier. Non-GAAP diluted EPS was $4.73, up 68.9%, and the company declared a quarterly dividend of $0.48 per share, up 9%. Second-quarter revenue guidance of $16.1 billion to $16.9 billion is below first-quarter revenue, and operating cash flow was negative $895.9 million in the quarter.
Revenue of $17.2 billion, up 18.1% year over year; non-GAAP gross billings of $25.8 billion, up 24.4%
GAAP diluted EPS of $4.04 versus $1.98; non-GAAP diluted EPS of $4.73 versus $2.80
Q2 fiscal 2026 outlook: revenue $16.1 billion to $16.9 billion; non-GAAP diluted EPS $3.75 to $4.25
Returned $118 million to stockholders ($80 million in buybacks, $39 million in dividends); $0.48 dividend payable April 29, 2026
FactSet reported second-quarter fiscal 2026 results for the three months ended February 28, 2026, with GAAP revenue up 7.1% year over year to $611.0 million. The company raised its fiscal 2026 GAAP and adjusted diluted EPS guidance, though GAAP diluted EPS fell 4.5% to $3.59 due mainly to higher operating expenses and an impairment charge.
GAAP revenue of $611.0 million, up 7.1% from $570.7 million; organic revenue grew 6.8% to $606.2 million
GAAP diluted EPS of $3.59, down 4.5% from $3.76; adjusted diluted EPS of $4.46, up 4.2% from $4.28
Fiscal 2026 GAAP diluted EPS guidance raised to $14.85 to $15.35 from $14.55 to $15.25; adjusted diluted EPS guidance raised to $17.25 to $17.75 from $16.90 to $17.60
Repurchased 651,750 shares for $163.0 million in the quarter; $697.1 million remained available under the program as of February 28, 2026
AIRO reported fourth-quarter and full-year 2025 results, with full-year revenue of $90.9 million, up from $86.9 million, and fourth-quarter revenue of $48.3 million, up from $39.7 million. The full-year net loss narrowed to $(4.1) million from $(38.7) million, but the operating loss widened to $(28.8) million and adjusted EBITDA fell to $5.7 million from $33.7 million, while the company's first 2026 outlook calls for revenue growth of 15% to 25%.
Full-year 2025 revenue of $90.9 million, up from $86.9 million in 2024; fourth-quarter revenue of $48.3 million, up from $39.7 million.
Full-year net loss of $(4.1) million, compared with $(38.7) million in 2024; operating loss widened to $(28.8) million from $(17.4) million.
Full-year gross margin fell to 59.9% from 67.1%; adjusted EBITDA was $5.7 million, compared with $33.7 million in 2024.
2026 outlook calls for revenue growth of 15% to 25% year over year; about $150 million of Drones backlog as of March 31, 2026.
McCormick reported first-quarter fiscal 2026 results for the quarter ended February 28, 2026, with net sales up 16.7% and adjusted earnings per share of $0.66 versus $0.60 a year earlier. The company reaffirmed its fiscal 2026 outlook, including adjusted earnings per share of $3.05 to $3.13, and reported reported EPS of $3.77, which includes a non-cash gain tied to its McCormick de Mexico acquisition.
Net sales rose 16.7% as reported and 1.2% organically; the January 2, 2026 McCormick de Mexico acquisition contributed 12.4%.
Adjusted operating income was $268 million versus $225 million a year earlier; reported operating income was $228 million.
Reported diluted EPS of $3.77 includes a $3.22 non-cash gain on remeasurement of the previously held McCormick de Mexico stake; special charges reduced EPS by $0.11.
Fiscal 2026 outlook reaffirmed: adjusted EPS growth of 2% to 5% and adjusted operating income growth of 16% to 20%.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.